Revenue segments as reported by the company.

Net revenue, before excise taxes

Excise taxes

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

Research and development

General and administrative

Restructuring costs

Share-based payments

Depreciation and amortization

Impairment loss on goodwill and indefinite-lived intangible assets

Impairment loss on long-lived assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cronos Group

Cronos Group, Inc. engages in the production and distribution of cannabis. Its brands include PEACE NATURALS, COVE, Spinach, Lord Jones, and PEACE+. The company was founded by Lorne Michael Gertner and Paul Rosen on August 21, 2012 and is headquartered in Toronto, Canada.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cronos Group, Inc. engages in the production and distribution of cannabis. I It operates through the Canada and Israel segments. The company was founded on August 21, 2012 and is headquartered in Toronto, Canada.

Cronos has taken a "slow and steady wins the race" approach to cannabis, with an obvious eye on a fully legalized American market. The case is slowly (and unevenly) playing out, with fermentation efforts progressing and the PharmaCann deal providing a first step into the U.S.

Is Cronos Stock Worth Buying? Probably, But Patience Remains A Requirement

Aurora Cannabis

Canopy Growth

Tilray Brands

Image Provided By Photo Stock Editor With the global legal marijuana market projected to reach $70.6 billion by 2028, more and more entrepreneurs and investors are looking for opportunities to get a foothold in this emerging industry. The specific applications and consumer trends that will take off in the coming years remains to be seen, but one of the most future-proof ways to  enter the cannabis industry is to get in on the cultivation side.

Indoor, Outdoor or Greenhouse: What to Look for in Different Cannabis Growing Properties

Anheuser-Busch InBev

Heineken NV

HEXO Corp

Altria

Constellation Brands

Molson Coors Brewing

Just because you can doesn't mean you should.

Maybe These Beverage Giants Should Have Stayed Away From Cannabis Drinks

Could These Canadian Marijuana Stocks Produce Gains This Summer? The post Looking For Marijuana Stocks To Watch In July? 2 Canadian Cannabis Stocks To Checkout appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Looking For Marijuana Stocks To Watch In July? 2 Canadian Cannabis Stocks To Checkout

TORONTO, June 25, 2021 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) announces that at its Annual Meeting of Shareholders held earlier today (the “Meeting”) there were 430 shareholders voting in person or by proxy holding in total 280,023,803 common shares of the Company, representing 75.35% of the total number of common shares of the Company outstanding.

Cronos Group Inc. Announces Results of 2021 Annual Meeting of Shareholders

The Small Exchange celebrated its one-year anniversary with the launch of the first futures contract on marijuana stocks. Small Cannabis, listed under the S420 symbol, is based on an index that includes 21 producers and distributors of medical and recreational cannabis products.

S420: The First Ever U.S. Cannabis Equity Index Future Contract

Cronos recently acquired an option to invest in a U.S.-based cannabis business.

This Canadian Cannabis Company Just Made a Big Move Toward U.S. Success

Best Canadian Marijuana Stocks To Watch Next Month The post 2 Top Canadian Marijuana Stocks To Watch Before July appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

2 Top Canadian Marijuana Stocks To Watch Before July

Amyris

Arena Pharmaceuticals

Innovative Industrial Properties

Coffee Holding

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.

Breaking Down a Wild Week in the World of Weed Stocks

Neptune Wellness Solutions Inc.

OrganiGram Holdings Inc.

When it comes to marijuana stocks to buy, I've always favored companies that go beyond the flower into edibles and cannabis-infused drinks.  The post 10 Marijuana Stocks to Buy for Their ‘Beyond the Flower' Plans appeared first on InvestorPlace.

10 Marijuana Stocks to Buy for Their ‘Beyond the Flower' Plans

cbdMD Inc

According to a recent report from ResearchAndMarkets.com, the global CBD market is expected to expand to $13.4 billion by 2028, reflecting a CAGR of over 21% from 2021 to 2028, making it one of the most explosive fast-growing markets in the developed-world economy. “Increasing awareness about the health benefits of cannabidiol (CBD), changing consumer opinion, […]

The Future of CBD is All About Distribution Positioning Like Real Brands Inc.

As New York's recreational cannabis industry shapes up, companies are making deals to take full advantage of the emerging market. On Monday, Cronos Group, a Canadian cannabis company backed by Altria, said it agreed to make a "strategic investment" in US cannabis company PharmaCann, which has operations in New York. Cronos paid $110.4 million for an option to acquire a 10.5% ownership stake in PharmaCann, once cannabis is federally legal in the US.

Canadian cannabis giant Cronos is making moves to enter the US. Its $110 million deal with PharmaCann would give Cronos access to New York's $7 billion market.

Are These Canadian Cannabis Stocks In A Loading Zone? The post Top Canadian Marijuana Stocks In June? 2 To Watch This Week appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Top Canadian Marijuana Stocks In June? 2 To Watch This Week

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Trulieve Cannabis Corp.

These marijuana stocks are absolute bargains. And they're poised to take off as cannabis becomes legal across the U.S. The post 7 Marijuana Stocks to Buy Now That Look Like Bargains appeared first on InvestorPlace.

7 Marijuana Stocks to Buy Now That Look Like Bargains

Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) is poised to acquire a stake in PharmaCann for approximately $110.4 million. Transaction Details: Under the terms of the agreement, a wholly-owned subsidiary of the Toronto-headquartered company has bought an option to obtain a roughly 10.5% ownership stake in PharmaCann on a fully diluted basis.

Cronos Group Shares Slightly Up After Announcing Purchase Of 10.5% Stake In PharmaCann For $110.4M

Cronos Group Inc. said Monday it has purchased an option to acquire a 10.5% stake in U.S. cannabis company PharmaCann in a deal valued at $110.4 million. Under the terms of the deal, the option can be exercised upon various factors, including the status of U.S. federal cannabis legalization, as well as regulatory approvals, including in states where PharmaCann operates.

Canadian cannabis company Cronos purchases option to acquire 10.5% stake in PharmaCann for $110.4 million

Investment is Expected to Position Cronos Group to Benefit from Rapid Growth in the  U.S. Cannabis Market

Cronos Group Announces Strategic Investment in PharmaCann, a Leading U.S. Cannabis Company

Cardiff Oncology

GrowGeneration Corp

Hawaiian Electric Industries

Village Farms International

22nd Century Group

Zynerba Pharmaceuticals

Smoked! How the Hottest Cannabis Stocks Fared This Week

Amplify Alternative Harvest ETF

Momentum traders are moving into marijuana stocks and their charts look great. Here are top picks in the industry if you want to play along.

3 Pot Plays That Are Lighting Up With Momentum

Cannabinoid company Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) is amending its previous partnership agreement with Ginkgo Bioworks, Inc., a company involved in cell programming. The amendment allows Cronos to start commercializing products with cultured cannabinoids before meeting the initially set productivity goals.

Cronos Group, Ginkgo Bioworks Modify Agreement To Speed Up Commercialization of Cultured Cannabinoids

Shares of this troubled marijuana grower are finally on the move, but does it mean you should buy them?

Up 20% Over a Few Days, Is Cronos a Stock You Can Count On?

Canadian cannabis company Cronos Group Inc. said Friday it has amended its agreement with Ginkgo Bioworks Inc. to accelerate the commercialization of cultured cannabinoids at scale. Cronos has had a research partnership with Ginkgo for several years with the aim of producing rare strains of cannabis that feature some of the 100 different cannabinoids, the compounds in the plant.

Canadian cannabis company Cronos amends agreement with Ginkgo, to issue up to 14.7 million shares

BOSTON and TORONTO, June 04, 2021 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group”), an innovative global cannabinoid company, and Ginkgo Bioworks, Inc. (“Ginkgo”), which is building the leading horizontal platform for cell programming, today announced an amended collaboration and license agreement (the “Amended Agreement”) that will enable the companies to accelerate the commercialization of cultured cannabinoids at scale.

Cronos Group and Ginkgo Bioworks Amend Agreement to Accelerate Commercialization of Cultured Cannabinoids and Cronos Group Begins Commercial Production of CBG

SNDL Inc.

Not all cannabis stocks will have investors seeing green.

3 Pot Stocks to Avoid Like the Plague in June

The marijuana industry is now an exciting place for traditional investors. If you discover the legal grey areas of this space, it could mean big things for your portfolio.

Marijuana Stocks on the Move

News for Cronos Group Stock (CRON)